Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Alcohol Addiction Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Alcohol Addiction Overview | 11 | 1 |
| Pipeline Products for Alcohol Addiction Comparative Analysis | 12 | 1 |
| Alcohol Addiction Therapeutics under Development by Companies | 13 | 2 |
| Alcohol Addiction Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Alcohol Addiction Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Alcohol Addiction Products under Development by Companies | 19 | 2 |
| Alcohol Addiction Products under Investigation by Universities/Institutes | 21 | 1 |
| Alcohol Addiction Companies Involved in Therapeutics Development | 22 | 26 |
| AbbVie Inc. | 22 | 1 |
| Addex Therapeutics Ltd | 23 | 1 |
| Adial Pharmaceuticals, LLC | 24 | 1 |
| Astraea Therapeutics, LLC | 25 | 1 |
| AstraZeneca Plc | 26 | 1 |
| Bionex Pharmaceuticals LLC | 27 | 1 |
| Bioprojet SCR | 28 | 1 |
| Cerecor Inc. | 29 | 1 |
| Curemark, LLC | 30 | 1 |
| Eli Lilly and Company | 31 | 1 |
| Ethypharm S.A. | 32 | 1 |
| Euthymics Bioscience, Inc. | 33 | 1 |
| H. Lundbeck A/S | 34 | 1 |
| Heptares Therapeutics Limited | 35 | 1 |
| Indivior Plc | 36 | 1 |
| Johnson &Johnson | 37 | 1 |
| Kinnov Therapeutics SAS | 38 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 39 | 1 |
| Lohocla Research Corporation | 40 | 1 |
| Omeros Corporation | 41 | 1 |
| Pfizer Inc. | 42 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 43 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 44 | 1 |
| VM Discovery, Inc. | 45 | 1 |
| XenoPort, Inc. | 46 | 1 |
| Zynerba Pharmaceuticals, Inc. | 47 | 1 |
| Alcohol Addiction Therapeutics Assessment | 48 | 12 |
| Assessment by Monotherapy Products | 48 | 1 |
| Assessment by Combination Products | 49 | 1 |
| Assessment by Target | 50 | 3 |
| Assessment by Mechanism of Action | 53 | 3 |
| Assessment by Route of Administration | 56 | 2 |
| Assessment by Molecule Type | 58 | 2 |
| Drug Profiles | 60 | 62 |
| (cyproheptadine hydrochloride + prazosin hydrochloride) Drug Profile | 60 | 1 |
| (disulfiram + selegiline) Drug Profile | 61 | 1 |
| A-705253 Drug Profile | 62 | 1 |
| ABT-436 Drug Profile | 63 | 1 |
| ADX-71441 Drug Profile | 64 | 4 |
| amitifadine Drug Profile | 68 | 2 |
| arbaclofen placarbil Drug Profile | 70 | 3 |
| AT-1001 Drug Profile | 73 | 1 |
| baclofen Drug Profile | 74 | 1 |
| carisbamate Drug Profile | 75 | 2 |
| CERC-501 Drug Profile | 77 | 2 |
| CM-1212 Drug Profile | 79 | 1 |
| Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders Drug Profile | 80 | 1 |
| gabapentin enacarbil ER Drug Profile | 81 | 4 |
| GET-73 Drug Profile | 85 | 1 |
| ibudilast Drug Profile | 86 | 8 |
| JDTic Drug Profile | 94 | 1 |
| JNJ-5234801 Drug Profile | 95 | 1 |
| nalmefene Drug Profile | 96 | 3 |
| naltrexone hydrochloride Drug Profile | 99 | 1 |
| naltrexone hydrochloride Drug Profile | 100 | 1 |
| odelepran hydrochloride Drug Profile | 101 | 1 |
| OMS-527 Drug Profile | 102 | 2 |
| ondansetron hydrochloride Drug Profile | 104 | 2 |
| PF-05190457 Drug Profile | 106 | 2 |
| pitolisant Drug Profile | 108 | 2 |
| saracatinib difumarate Drug Profile | 110 | 2 |
| SKL-10406 Drug Profile | 112 | 1 |
| Small Molecule for Alcohol Addiction Drug Profile | 113 | 1 |
| Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction Drug Profile | 114 | 1 |
| Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC Drug Profile | 115 | 1 |
| Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders Drug Profile | 116 | 2 |
| Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders Drug Profile | 118 | 1 |
| Small Molecules to Agonize NOP for Pain and Alcohol Addiction Drug Profile | 119 | 1 |
| Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety Drug Profile | 120 | 1 |
| VMD-2202 Drug Profile | 121 | 1 |
| Alcohol Addiction Dormant Projects | 122 | 3 |
| Alcohol Addiction Discontinued Products | 125 | 1 |
| Alcohol Addiction Product Development Milestones | 126 | 11 |
| Featured News &Press Releases | 126 | 1 |
| Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana | 126 | 1 |
| May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana | 126 | 1 |
| Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor s Oral Kappa Opioid Receptor Antagonist, CERC-501 | 127 | 1 |
| Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting | 128 | 1 |
| Oct 13, 2015: Addex ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder | 128 | 1 |
| Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director | 129 | 1 |
| Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence | 130 | 1 |
| Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder | 131 | 1 |
| Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting | 131 | 1 |
| Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder | 132 | 1 |
| Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder | 133 | 1 |
| Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro | 134 | 1 |
| Nov 26, 2014: Drug recommended to help cut drink dependence | 134 | 1 |
| Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder | 135 | 1 |
| Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence | 136 | 1 |
| Appendix | 137 | 2 |
| Methodology | 137 | 1 |
| Coverage | 137 | 1 |
| Secondary Research | 137 | 1 |
| Primary Research | 137 | 1 |
| Expert Panel Validation | 137 | 1 |
| Contact Us | 137 | 1 |
| Disclaimer | 138 | 1 |